Who makes Intranasal Ketoralac?

Intranasal Ketoralac is developed by Montefiore Medical Center.

What development phase is Intranasal Ketoralac in?

Intranasal Ketoralac is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Intranasal Ketoralac

Montefiore Medical Center · FDA-approved active Small molecule Quality 0/100

Intranasal Ketoralac, marketed by Montefiore Medical Center, is a non-opioid analgesic currently available in the market. The key composition patent for the drug is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Intranasal Ketoralac
Also known as	Sprix
Sponsor	Montefiore Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Use of Intranasal Ketoralac for Pain Management (Sprix) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Intranasal Ketoralac CI brief — competitive landscape report
Intranasal Ketoralac updates RSS · CI watch RSS
Montefiore Medical Center portfolio CI